¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Other leukaemia of unspecified cell type"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • fat cell
    Áö¹æ¼¼Æ÷
  • fat-storing cell
    Áö¹æÀúÀå¼¼Æ÷
  • flagellated cell
    Æí¸ð¼¼Æ÷
  • flame cell
    ºÒ²É¼¼Æ÷
  • fluorescence activated cell sorter
    Çü±¤Ç¥Áö¼¼Æ÷ºÐ·ù±â
  • foam cell
    °Åǰ¼¼Æ÷
  • follicle cell
    1. ¼ÒÆ÷¼¼Æ÷ 2. ³­Æ÷¼¼Æ÷
  • follicular cell
    1. ¼ÒÆ÷¼¼Æ÷ 2. ³­Æ÷¼¼Æ÷
  • foreign body giant cell
    À̹°°Å´ë¼¼Æ÷
  • fusiform cell
    ¹æÃß¼¼Æ÷
  • G cell
    G¼¼Æ÷
  • Gaucher cell
    °í½¦¼¼Æ÷
  • germ cell
    Á¾ÀÚ¼¼Æ÷, »ý½Ä¼¼Æ÷, ¹è¼¼Æ÷
  • germinal cell
    Á¾ÀÚ¼¼Æ÷
  • ghost cell
    À¯·É¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • egg cell
    ³­¼¼Æ÷, ¾Ë¼¼Æ÷
  • endothelial cell
    ³»ÇǼ¼Æ÷
  • enterochromaffine cell
    âÀÚģũ·Ò¼¼Æ÷, âÀÚÅ©·Òģȭ¼¼Æ÷
  • eosinophilic cell
    È£»ê¼¼Æ÷
  • ependymal cell
    ³ú½Ç¸·¼¼Æ÷
  • epidermal cell
    Ç¥ÇǼ¼Æ÷
  • epithelial cell
    »óÇǼ¼Æ÷
  • epithelioid cell
    »óÇǸð¾ç¼¼Æ÷
  • erythroid cell
    (¢¡red blood cell) ÀûÇ÷±¸
  • ethmoidal cell
    ¹úÁý»À¹úÁý, »ç°ñºÀ¼Ò
  • ethmoidal air cell
    ¹úÁý»À¹úÁý, »ç°ñ¹úÁý
  • eukaryotic cell
    ÁøÇÙ¼¼Æ÷
  • fat cell
    Áö¹æ¼¼Æ÷
  • fat-storing cell
    Áö¹æÀúÀå¼¼Æ÷
  • flagellated cell
    Æí¸ð¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • antigen reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷.
  • apex of cell
    ¼¼Æ÷²À´ë±â
  • apical cell
    Á¤(´Ü)¼¼Æ÷(ð¢Ó®á¬øà)
  • argentaffin chromaffin cell
    Å©·Òģȭ¼º ¼¼Æ÷
  • argyrophil(e) cell
    ÀºÄ£È­¼º ¼¼Æ÷(ëÞöÑûúàõá¬øà)
  • arsenical basal cell carcinoma
    ºñ¼Ò¼º(Ý÷áÈàõ) ±âÀú¼¼Æ÷¾Ï
  • arteritis,giant cell of aorta
    ´ëµ¿¸Æ(ÓÞÔÑØæ)ÀÇ °Å¼¼Æ÷¼º(ËÝá¬øààõ)
  • free cell
    ÀÚÀ¯¼¼Æ÷(í»ë¦á¬øà).
  • functional cell
    ±â´É¼¼Æ÷(ѦÒöá¬øà).
  • funicular cell
    ÁÙ¼¼Æ÷, »è¼¼Æ÷(ßãá¬øà).
  • fusiform cell
    ¹æÃß¼¼Æ÷
  • fusiform endothelial cell
    ¹æÃß³»ÇǼ¼Æ÷
  • fusiform myoepithelial cell
    ¹æÃßÇü ±Ù»óÇÇ ¼¼Æ÷
  • fusiform myoepithelial cell
    ¹æÃß±ÙÀ°»óÇǼ¼Æ÷
  • fusion, cell
    ¼¼Æ÷À¶ÇÕ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • type I human t lymphotropic virus
    IÇü ÀÎ t ¸²ÇÁ¿µ¾ç¼º ¹ÙÀÌ·¯½º
  • type I hyperlipoproteinemia
    I Çü °úÁö´Ü¹éÇ÷Áõ
  • type II glycogen storage disease
    ´ç¿øÀúÀ庴IIÇü(ÓØê«îÍíúÜ»ì£úþ).
  • type II human T lymphotropic virus
    II Çü ÀÎ T ¸²ÇÁ¿µ¾ç¼º ¹ÙÀÌ·¯½º
  • type III human T lymphotropic virus
    IIIÇü ÀÎ t¸²ÇÁ¿µ¾ç¼º ¹ÙÀÌ·¯½º
  • type a encephalitis
    ±â¸é¼º ³ú¿°(ÐîØùàõÒàæú)
  • type a spermatogonium
    À¸¶äÁ¤Á¶¼¼Æ÷
  • type b encephalitis =japanese e.
    BÇü ³ú¿°
  • type b spermatogonium
    ´ÊÁ¤Á¶¼¼Æ÷
  • type culture
    Ç¥Áعè¾ç
  • type culture
    ´ëÇ¥(±ÕÁ¾)¹è¾ç(ÓÛøúжðúÛÆå×), Ç¥Áعè¾ç(øöñÞÛÆå×).
  • type culture
    ´ëÇ¥(±ÕÁ¾)¹è¾ç(ÓÛøúжðúÛÆå×), Ç¥Áعè¾ç(øöñÞÛÆå×).
  • type culture collection
    Ç¥ÁرÕÁÖ¼ö·Ï(¡­Ð¶ñ»â¥ÒÓ).
  • type of respiration
    È£ÈíÇü(û¼ýåúþ).
  • type species
    Ç¥ÁرÕÁ¾(øöñÞжðú).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
  • Paneth cell
    È£»ê¼º°ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] »êÈ£¼º°ú¸³¼¼Æ÷
  • Acidophilic cell
    È£»ê¼º¼¼Æ÷
    [¿¾ ¿ë¾î] »êÈ£¼º¼¼Æ÷
  • Basophilic cell
    È£¿°±â¼º¼¼Æ÷
    [¿¾ ¿ë¾î] ¿°±âÈ£¼º¼¼Æ÷
  • Unilocular fat cell
    ȬĭÁö¹æ¼¼Æ÷
    [¿¾ ¿ë¾î] ´Ü¹æ¼ºÁö¹æ¼¼Æ÷
  • Uninuclear giant cell
    ȬÇÙ°Å´ë¼¼Æ÷
    [¿¾ ¿ë¾î] ´ÜÇÙ¼º°Å´ë¿µ¾ç¸·¼¼Æ÷
  • Olfactory cell
    Èİ¢¼¼Æ÷
    [¿¾ ¿ë¾î] Èİ¢¼¼Æ÷
  • Spinous cell
    °¡½Ã¼¼Æ÷
    [¿¾ ¿ë¾î] À¯±Ø¼¼Æ÷
  • Dendriform cell
    ³ª¹µ°¡Áö¼¼Æ÷
    [¿¾ ¿ë¾î] ¼öÁö»ó¼¼Æ÷
  • Endocrine cell
    ³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ³»ºÐºñ¼¼Æ÷
  • Colliculiform cell
    µÐ´ö¼¼Æ÷
    [¿¾ ¿ë¾î] ¼Ò±¸¼¼Æ÷
  • Microvillous cell
    ¹Ì¼¼À¶¸ð¼¼Æ÷
    [¿¾ ¿ë¾î] ¹Ì¼¼À¶¸ð¼¼Æ÷
  • Smooth muscle cell
    ¹Î¹«´Ì±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] ÆòȰ±Ù±Ù¼¼Æ÷
  • Light cell
    ¹àÀº¼¼Æ÷
    [¿¾ ¿ë¾î] ¸í¼¼Æ÷
  • Light cell
    ¹àÀº¼¼Æ÷
    [¿¾ ¿ë¾î] ¸íÁÖ¼¼Æ÷
  • Fusiform cell
    ¹æÃß¼¼Æ÷
    [¿¾ ¿ë¾î] ¹æÃ߻󼼯÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 13
GIDAANT Gender Identity Disorder of Adolescence or Adulthood, Non-transsexual Type
HBPV Haemophilus influenza type B Polysaccharide(PRP) Vaccine; BÇü Çì¸ðÇʷ罺 ÀÎÇ÷翣ÀÚ ÇǸ· ´Ù´çÁú ¹é½Å...
Hib Haemophilus Influenzae B type; B Çü ÀÎÇ÷翣ÀÚ±Õ
IDDM Insulin Dependent Diabetes Mellitus
  = Type I DM
NIDDM Non-Insulin Dependent Diabetes Mellitus
  = Type II DM
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 13
PML Promyelocytic leukaemia protein
RBL Rat basophil leukaemia
RBL Rat basophilic leukaemia
RBL-1 Rat basophilic leukaemia
RBL-2H3 Rat basophilic leukaemia cells
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cell-mediated cytotoxicity
    ¼¼Æ÷ ¸Å°³¼º ¼¼Æ÷ µ¶¼º
    Ç×ü ȤÀº lym
  • cell-mediated hypersensitivity
    ¼¼Æ÷ ¸Å°³¼º °ú¹ÎÁõ
    TuberculinÇü Çdz» ¹ÝÀÀÀ» ´ëÇ¥·Î ÇÑ´Ù. ¼¼Æ÷¼º ¸é¿ª ¹ÝÀÀÀÇ ÇÑ ÇüÅÂ. Ç׿ø¿¡ ÀÇÇÏ¿© °¨ÀÛµÈ µ¿¹°ÀÇ Çdz»¿¡ ÀçÂ÷ Ç׿øÀ» ÁÖ»çÇÔÀ¸·Î½á ¼ö ½Ã°£À¸·ÎºÎÅÍ 36½Ã°£ ÈÄ¿¡ ¹ßÀû, °æ°áÀ» ¼ö¹Ý½ÃŰ´Â Á¾Ã¢ÀÌ ÁÖ»ç ºÎÀ§¿¡ ¹ß»ýÇÏ´Â ¹ÝÀÀÀÌ´Ù.
  • cell-mediated immunity
    ¼¼Æ÷ ¸Å°³ ¸é¿ª, ¼¼Æ÷ ¸Å°³¼º ¸é¿ª
  • cell-mediated immunodeficiency syndrome
    ¼¼Æ÷¼º ¸é¿ª °áÇÌ ÁõÈıº
  • central giant cell
    °ñ³» °Å´ë ¼¼Æ÷
  • central giant cell tumor
    Á߽ɼº °Å´ë ¼¼Æ÷ ¾ÏÁ¾
  • central pain transmission cell
    ÁßÃß¼º ÅëÁõ Àü´Þ ¼¼Æ÷, ÁßÃß µ¿Åë Àü´Þ ¼¼Æ÷
  • centroacinar cell
    ²Ê¸® Á᫐ ¼¼Æ÷, »ùÆ÷ Á᫐ ¼¼Æ÷
  • clear cell
    Åõ¸í ¼¼Æ÷
    ±¸°­ »óÇÇÀÇ Á¶Á÷ Ç¥º»¿¡¼­ ´Ù¸¥ »óÇÇ ¼¼Æ÷¿Í´Â ´Þ¸® ÇÙ ÁÖÀ§¿¡ Åõ¸íÇÑ Èı¤
  • clear cell acanthoma
    Åõ¸í ¼¼Æ÷ ±Ø¼¼Æ÷Á¾
  • clear cell hidradenoma
    Åõ¸í ¼¼Æ÷ ÇѼ±Á¾
  • clear cell sarcoma
    Åõ¸í ¼¼Æ÷ À°Á¾
  • cleared cell
    Åõ¸í ¼¼Æ÷
  • columnar cell carcinoma
    ¿øÁÖ ¼¼Æ÷ ¾ÏÁ¾
  • columnar epithelial cell
    ¿øÁÖ »óÇÇ ¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 13
haemophilus influenzae type b The majority of type b isolates are from biotype I. The organism can cause life-threatening meningitis, primarily in children 6-12 months of age. Children with underlying disease or immunodeficiency are also at high risk for infection. A vaccine is available and recommended for children under 5 years of age.
(12 Dec 1998)
haemophilus influenzae type b immunization See HIB immunization,
(12 Dec 1998)
Haemophilus influenzae type B vaccine A conjugate of oligosaccharides of the capsular antigen of H. Influenzae type B and diphtheria CRM protein.
(05 Mar 2000)
pre-excitation, mahaim-type A form of pre-excitation characterised by a normal pr interval and a long qrs interval with a delta wave.
(12 Dec 1998)
Hermansky-Pudlak syndrome type VI An autosomal recessive deficiency of pigment in skin, hair, and eyes; in the tyrosinase negative type, there is an absence of tyrosinase; in the tyrosinase positive type, there is normal tyrosinase which cannot enter pigment cells; it is transmitted by an autosomal recessive inheritance. The compound heterozygote is normal so the two forms are not allelic.
There are several types: type IA is characterised by absence of tyrosinase with life-long complete absence of melanin, marked photophobia, and nystagmus. Type IB, yellow albinism with low or absent tyrosinase; improves with age.
Type II, with normal tyrosinase activity is the most common; hair darkens and nevi and freckles develop.
Type III is characterised by absent tyrosinase but pigmentation of the iris in the first decade.
Type IV in Africans with normal tyrosinase.
Type V with red hair.
Type VI, Hermansky-Padlak syndrome, with haemorrhage due to platelet deficiency and low to absent tyrosinase.
Synonym: Hermansky-Pudlak syndrome type VI.
(05 Mar 2000)
herpes simplex type 1 A virus that causes cold sores and fever blisters.
(12 Dec 1998)
herpes simplex type 2 Different from herpes simplex type 1, herpes simplex 2 causes genital herpes.
(12 Dec 1998)
herpes simplex virus type 1 UL13 protein kinase <enzyme> Phosphorylates icp22 and involved in the accumulation of alpha and gamma mrnas and proteins in the infected cells; aa sequence has been determined
Registry number: EC 2.7.1.-
Synonym: ul13 protein kinase, hsv-1, hsv-1 ul13 protein, hsv-1 ul13 pk, u(l)13 protein kinase, protein kinase ul13
(26 Jun 1999)
protoporphyrinogen type III The immediate precursor of protoporphyrin III in haem biosynthesis; elevated in cases of variegate porphyria.
(05 Mar 2000)
protoporphyrinogen type III oxidase A mitochondrial enzyme that uses O2 to convert protoporphyrinogen type III to protoporphyrin type III in haem biosynthesis; a deficiency of this enzyme is associated with variegate porphyria.
(05 Mar 2000)
protoporphyrin type III 2,7,12,18-Tetramethyl-3,8-divinylporphin-13,17dipropionic acid;the principal protoporphyrin found in nature (one of 15 possible isomers), characterised by the presence of 4 methyl groups, 2 vinyl groups, and 2 propionic acid side chains; a porphyrin derivative that, with iron, forms the haem of haemoglobin and the prosthetic groups of myoglobin, catalase, cytochromes, etc.
(05 Mar 2000)
P-type ATPase <enzyme> One of three major classes of ion transport ATPases, characterised by vanadate sensitivity and a phosphorylated intermediate. The archetype is the sodium pump.
See: F-type ATPase, V-type ATPase.
(18 Nov 1997)
H-type fistula <gastroenterology, surgery> A rare form of congenital tracheoesophageal fistula in which there is no oesophageal atresia, manifest as aspiration pneumonias.
Synonym: H-type tracheoesophageal fistula.
(05 Mar 2000)
H-type tracheoesophageal fistula <gastroenterology, surgery> A rare form of congenital tracheoesophageal fistula in which there is no oesophageal atresia, manifest as aspiration pneumonias.
Synonym: H-type tracheoesophageal fistula.
(05 Mar 2000)
serine-type D-Ala-D-Ala carboxypeptidase <enzyme> Cleaves between d-ala residues of bacterial cell wall peptidoglycan; also catalyses transpeptidation of peptidyl-alanyl moieties that are n-acyl substituents of d-alanine
Registry number: EC 3.4.16.4
Synonym: ala-ala carboxypeptidase, serine-type, dd-peptidase, d-alanyl-d-alanine-carboxypeptidase
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 13
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 13
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 13
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 13
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 13
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 13
ÅëÇÕ°Ë»ö ¿Ï·á